STEERING COMMITTEE K.-U. Eckardt / F. Edelmann / M. Endres / H. Gerhardt / N. Hübner / T. Kurth / U. Landmesser / D.M. Leistner / K. Mai / D.N. Müller / P. Pieske / T. Pischon / G. Rauch/ K. Schmidt-Ott / J. Schulz-Menger / B. Singerink / J. Spranger THE GENERAL CONCEPT Aims Improve prediction and mechanistic understanding of cardiovascular disease progression and outcomes in patients in very high risk in order to provide the basis for improved, individualized management. Strategy Combining cutting edge phenotyping technologies with short- and long-term observation in patients with distinct cardiovascular disease manifestations to identify a) unifying and divergent mechanisms of disease progression b) endogenous protective mechanisms c) risk factors d) novel therapeutic targets e) cross-organ interactions f) methods of improved risk prediction based on complex data analysis Recognize risks. Understanding interrelations. Figure 2: Study design. Follow-up timeline and procedures of the BeLOVE initiative INNOVATION BeLOVE is open to new research hypotheses developed by the broad scientific community of the BIH, Charité, and MDC. However, it focuses on three overarching themes: 1. Disease overarching mechanisms (e.g., microbiome & immune homeostasis, body composition & metabolic function) 2. Risk prediction & target identification (e.g., early vs. late, risk stratification, cross-over risk, comprehensive risk models, machine-learning techniques) 3. Interaction between diseases and organ systems (systemic effects of vascular events, organ- interaction, effects on remote organs) SHORT SUMMARY Figure 1: General concept of BeLOVE. (Acute heart failure (AHF), Acute coronary syndrome (ACS), Acute cerebrovascular disorders (stroke), Acute kidney injury stage 2 or 3 lasting ≥72h (AKI), Type 2 diabetes mellitus (T2DM) METHOD The objective of BeLOVE is to identify novel pathophysiological cross-disease mechanisms and treatment targets that determine both short and long-term outcome of high-risk patients with acute vascular disease (i.e., acute cerebrovascular disorder, acute coronary syndrome, acute heart failure, and acute kidney injury) and diabetes. With an interdisciplinary approach and deep phenotyping, BeLOVE will investigate the impact of systemic factors and co-morbidities (e.g. retinopathy, kidney dysfunction) on risk and prognosis of these vascular diseases as well as effects of specific/individual vascular events on remote organs (e.g., neurocardiogenic damage after stroke, cognitive deficits after acute cardiovascular events. BeLOVE will provide a uniform and standardized backbone phenotyping of all patients, but enables different levels of participation and combination with modules for additional disease-specific testing. Broad participation of basic and clinical scientists as well as clinical epidemiologists from BIH, Charité, and MDC will promote the identification of cross-disease mechanisms (e.g., contribution of gut microbiome, immune system, metabolic factors, stress, vascular function, (epi)genetic factors). BeLOVE serves as a unique resource of integrated high quality biomedical data and biomaterials open to the BIH community for testing of current and future research hypotheses.

STEERING COMMITTEE SHORT SUMMARY · and diabetes. With an interdisciplinary approach and deep phenotyping, BeLOVE will investigatethe impact of systemic factors and co-morbidities

Download PDF Report

Upload
others
View
3
Download
0

Embed Size (px)

Citation preview

Page 1: STEERING COMMITTEE SHORT SUMMARY · and diabetes. With an interdisciplinary approach and deep phenotyping, BeLOVE will investigatethe impact of systemic factors and co-morbidities

THE GENERAL CONCEPTAimsImprove prediction and mechanistic understanding of cardiovasculardisease progression and outcomes in patients in very high risk inorder to provide the basis for improved, individualized management.

StrategyCombining cutting edge phenotyping technologies with short- andlong-term observation in patients with distinct cardiovascular diseasemanifestations to identifya) unifying and divergent mechanisms of disease progressionb) endogenous protective mechanismsc) risk factorsd) novel therapeutic targetse) cross-organ interactionsf) methods of improved risk prediction based on complex data

analysis

Recognize risks. Understanding interrelations.

Figure 2: Study design. Follow-up timeline and procedures of the BeLOVE initiative

INNOVATIONBeLOVE is open to new research hypotheses developed by the broad scientific community of the BIH, Charité, and MDC. However, it focuses on three overarching themes:1. Disease overarching mechanisms (e.g., microbiome

& immune homeostasis, body composition & metabolic function)

2. Risk prediction & target identification (e.g., early vs. late, risk stratification, cross-over risk, comprehensive risk models, machine-learning techniques)

3. Interaction between diseases and organ systems (systemic effects of vascular events, organ-interaction, effects on remote organs)

SHORT SUMMARY

Figure 1: General concept of BeLOVE. (Acute heart failure (AHF), Acute coronary syndrome (ACS), Acute cerebrovascular disorders (stroke), Acute kidney injury stage 2 or 3 lasting ≥72h (AKI), Type 2 diabetes mellitus (T2DM)

METHOD

The objective of BeLOVE is toidentify novel pathophysiologicalcross-disease mechanisms andtreatment targets that determineboth short and long-termoutcome of high-risk patients withacute vascular disease (i.e., acutecerebrovascular disorder, acutecoronary syndrome, acute heartfailure, and acute kidney injury)and diabetes. With aninterdisciplinary approach anddeep phenotyping, BeLOVE willinvestigate the impact of systemicfactors and co-morbidities (e.g.

retinopathy, kidney dysfunction)on risk and prognosis of thesevascular diseases as well aseffects of specific/individualvascular events on remote organs(e.g., neurocardiogenic damageafter stroke, cognitive deficitsafter acute cardiovascular events.BeLOVE will provide a uniformand standardized backbonephenotyping of all patients, butenables different levels ofparticipation and combinationwith modules for additionaldisease-specific testing. Broad

participation of basic and clinicalscientists as well as clinicalepidemiologists from BIH, Charité,and MDC will promote theidentification of cross-diseasemechanisms (e.g., contribution ofgut microbiome, immune system,metabolic factors, stress, vascularfunction, (epi)genetic factors).BeLOVE serves as a uniqueresource of integrated highquality biomedical data andbiomaterials open to the BIHcommunity for testing of currentand future research hypotheses.